| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33074 | |||
| IHC-Prediluted | NBP2-44976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-62555-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-73200 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-43954 | |||
| BSA Free | NBP2-34495-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-93832-0.02ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-89133-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-37736-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-38759-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-74053 | |||
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0010.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - p53 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using a 1 ug/mL mouse anti-p53 monoclonal (NBP2-29453, Novus Biologicals) for 1 hour at room temperature followed by the appropriate HRP polymer reagent, anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0008.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Analysis of p53 1) A431 2) MCF7 and 3) HEK293 lysate probed with p53 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0001.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - Formalin-paraffin human colon carcinoma stained with p53 Ab (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0003.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Simple Western lane view shows a specific band for p53 in 0.2 mg/ml of MDA-MB-231 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0004.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Electropherogram image of the corresponding Simple western lane view. p53 antibody was used at 10 ug/ml dilution on MDA-MB-231 lysate(s) respectively.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0005.jpg)
![Western Blot: p53 Antibody (PAb421) - Chimeric [NBP2-62555] - Western Blot using anti-p53 antibody PAb421 A431 cell nuclear (A) and cytoplasmic (B) extract (35ug protein in RIPA buffer) was resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit version of PAb421 (NBP2-62555) at 0.1 ug/ml before detection by an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected band size for p53 is 43.7 kDa, though due to the high number of proline residues in this protein runs at a size of ~53kDa (c.f. Ziemer et al., PMID: 7107651). NBP2-62555 successfully detected both human nuclear and cytoplasmic p53.](http://images.novusbio.com/fullsize/p53-Antibody-PAb421-Chimeric-Western-Blot-NBP2-62555-img0003.jpg "Western Blot: p53 Antibody (PAb421) - Chimeric [NBP2-62555] - Western Blot using anti-p53 antibody PAb421 A431 cell nuclear (A) and cytoplasmic (B) extract (35ug protein in RIPA buffer) was resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit version of PAb421 (NBP2-62555) at 0.1 ug/ml before detection by an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected band size for p53 is 43.7 kDa, though due to the high number of proline residues in this protein runs at a size of ~53kDa (c.f. Ziemer et al., PMID: 7107651). NBP2-62555 successfully detected both human nuclear and cytoplasmic p53.")
![Flow Cytometry: p53 Antibody (PAb421) - Chimeric [NBP2-62555] - Flow-cytometry using the anti-p53 antibody PAb421. Jurkat cells were stained with unimmunized rabbit IgG antibody (black line) or the rabbit-chimeric version of PAb421 (NBP2-62555, blue line) at a concentration of 10 ug/ml for 30 mins at RT. After washing, bound antibody was detected using anti-rabbit IgG JK (FITC-conjugate) antibody at 2 ug/ml and cells analyzed on a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/p53-Antibody-PAb421-Chimeric-Flow-Cytometry-NBP2-62555-img0002.jpg)
![Immunocytochemistry /Immunofluorescence: p53 Antibody (PAb421) - Chimeric - Azide and BSA Free [NBP2-62555] - Immunofluorescence analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton and stained with NBP2-62555 at 10ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1ug/ml), showing nuclear staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-62555, DAPI, merged channels and a negative control. The negative control was stained with unimmunized rabbit IgG followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nbp2-62555_rabbit-monoclonal-p53-antibody-pab421-chimeric-7420252226522.png)
![Western Blot: p53 Antibody (5E2) [NBP2-00723] - Analysis of extracts (35ug) from 9 different cell lines by using anti-p53 monoclonal antibody.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Western-Blot-NBP2-00723-img0018.jpg "Western Blot: p53 Antibody (5E2) [NBP2-00723] - Analysis of extracts (35ug) from 9 different cell lines by using anti-p53 monoclonal antibody.")
![Immunocytochemistry/Immunofluorescence: p53 Antibody (5E2) [NBP2-00723] - Staining of COS7 cells transiently transfected by pCMV6-ENTRY p53.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Immunocytochemistry-Immunofluorescence-NBP2-00723-img0013.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (5E2) [NBP2-00723] - Staining of paraffin-embedded Carcinoma of Human pancreas tissue using anti-p53 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Immunohistochemistry-Paraffin-NBP2-00723-img0016.jpg)
![Flow Cytometry: p53 Antibody (5E2) [NBP2-00723] - HEK293T cells transfected with either overexpression plasmid (Red) or empty vector control plasmid (Blue) were immunostained by anti-p53 antibody, and then analyzed by flow cytometry.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Flow-Cytometry-NBP2-00723-img0012.jpg)
![Western Blot: p53 Antibody (5E2) [NBP2-00723] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY p53 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-p53.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Western-Blot-NBP2-00723-img0017.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (5E2) [NBP2-00723] - Staining of paraffin-embedded Adenocarcinoma of Human ovary tissue using anti-p53 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Immunohistochemistry-Paraffin-NBP2-00723-img0014.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (5E2) [NBP2-00723] - Staining of paraffin-embedded Carcinoma of Human lung tissue using anti-p53 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Immunohistochemistry-Paraffin-NBP2-00723-img0015.jpg)
![Flow Cytometry: p53 Antibody (5E2) [NBP2-00723] - Analysis of Hela cells, using anti-p53 antibody, (Red), compared to a nonspecific negative control antibody (Blue).](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Flow-Cytometry-NBP2-00723-img0011.jpg)
![Simple Western: p53 Antibody (5E2) [NBP2-00723] - Simple Western lane view shows a specific band for p53 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-5E2-Simple-Western-NBP2-00723-img0010.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (CL2199) [NBP2-34495] - Staining in human skin and skeletal muscle tissues. Corresponding p53 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunohistochemistry-Paraffin-NBP2-34495-img0021.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: p53 Antibody (CL2199) [NBP2-34495] - Staining in human skin and skeletal muscle tissues. Corresponding p53 RNA-seq data are presented for the same tissues.")
![<b>Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: p53 Antibody (CL2199) [NBP2-34495] - Analysis of extracts from U-251 cells, transfected with: control siRNA, target specific siRNA probe #1, target specific siRNA probe #2, using Anti-P53 monoclonal antibody. Downregulation of antibody signal confirms target specificity. Remaining % intensity, relative control lane, is indicated. Anti-PPIB monoclonal antibody was used as loading control.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Western-Blot-NBP2-34495-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (CL2199) [NBP2-34495] - Staining in U2OS cell line with Anti-p53 monoclonal antibody, showing cell cycle dependent nuclear (without nucleoli) staining in green. Microtubule- and nuclear probes are visualized in red and blue respectively (where available). Antibody staining is shown in green.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunocytochemistry-Immunofluorescence-NBP2-34495-img0014.jpg)
![Western Blot: p53 Antibody (CL2199) [NBP2-34495] - Lane 1: Marker [kDa] Lane 2: Human cell line U-251](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Western-Blot-NBP2-34495-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (CL2199) [NBP2-34495] - Staining of human cell line A431 showing cell cycle dependent nuclear (without nucleoli)Staining in green. Microtubule-staining and nuclear probes are visualized in red and blue respectively (where available). Antibody staining is shown in green](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunocytochemistry-Immunofluorescence-NBP2-34495-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (CL2199) [NBP2-34495] - Staining in MCF7 cell line with Anti-p53 monoclonal antibody, showing cell cycle dependent nuclear (without nucleoli) staining in green. Microtubule- and nuclear probes are visualized in red and blue respectively (where available). Antibody staining is shown in green.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunocytochemistry-Immunofluorescence-NBP2-34495-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (CL2199) [NBP2-34495] - Staining in U251 cell line with Anti-p53 monoclonal antibody, showing cell cycle dependent nuclear (without nucleoli) staining in green. Microtubule- and nuclear probes are visualized in red and blue respectively (where available). Antibody staining is shown in green.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunocytochemistry-Immunofluorescence-NBP2-34495-img0013.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (CL2199) [NBP2-34495] - Staining of human colorectal cancer shows strong nuclear positivity in tumor cells, but not in normal mucosa.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunohistochemistry-Paraffin-NBP2-34495-img0017.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (CL2199) [NBP2-34495] - Staining of human lung cancer (squamous cell carcinoma) shows strong nuclear positivity in tumor cells.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunohistochemistry-Paraffin-NBP2-34495-img0018.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (CL2199) [NBP2-34495] - Staining of human skin shows moderate to strong nuclear positivity in a subset of epidermal cells.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunohistochemistry-Paraffin-NBP2-34495-img0019.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (CL2199) [NBP2-34495] - Staining of human skeletal muscle shows no positivity in striated muscle fibers as expected.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Immunohistochemistry-Paraffin-NBP2-34495-img0020.jpg)
![Simple Western: p53 Antibody (CL2199) [NBP2-34495] - Simple Western lane view shows a specific band for P53 in 0.2 mg/ml of Hek293T lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Simple-Western-NBP2-34495-img0009.jpg)
![Simple Western: p53 Antibody (CL2199) [NBP2-34495] - Electropherogram image(s) of corresponding Simple Western lane view. p53 antibody was used at 1:50 dilution on Hek293T lysate(s).](http://images.novusbio.com/fullsize/p53-Antibody-CL2199-Simple-Western-NBP2-34495-img0011.jpg)
![Western Blot: MT-ND3 Antibody [NBP2-93832] - Analysis of extracts of various cell lines, using MT-ND3 antibody at 1:500 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit. Exposure time: 90s.](http://images.novusbio.com/fullsize/MT-ND3-Antibody-Western-Blot-NBP2-93832-img0007.jpg "Western Blot: MT-ND3 Antibody [NBP2-93832] - Analysis of extracts of various cell lines, using MT-ND3 antibody at 1:500 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit. Exposure time: 90s.")
![Immunocytochemistry/Immunofluorescence: MT-ND3 Antibody [NBP2-93832] - Analysis of L929 cells using MT-ND3 at dilution of 1:100. Blue: DAPI for nuclear staining.](http://images.novusbio.com/fullsize/MT-ND3-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-93832-img0001.jpg)
![Immunohistochemistry-Paraffin: MT-ND3 Antibody [NBP2-93832] - Mouse kidney using MT-ND3 antibody at dilution of 1:100 (40x lens).Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/MT-ND3-Antibody-Immunohistochemistry-Paraffin-NBP2-93832-img0004.jpg)
![Immunohistochemistry-Paraffin: MT-ND3 Antibody [NBP2-93832] - Human appendix using MT-ND3 antibody at dilution of 1:100 (40x lens).Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/MT-ND3-Antibody-Immunohistochemistry-Paraffin-NBP2-93832-img0002.jpg)
![Immunohistochemistry-Paraffin: MT-ND3 Antibody [NBP2-93832] - Human colon carcinoma using MT-ND3 antibody at dilution of 1:100 (40x lens).Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/MT-ND3-Antibody-Immunohistochemistry-Paraffin-NBP2-93832-img0003.jpg)
![Immunoprecipitation: MT-ND3 Antibody [NBP2-93832] - Analysis of 200ug extracts of HeLa cells using 3ug MT-ND3 antibody. Western blot was performed from the immunoprecipitate using MT-ND3 antibody at a dilition of 1:500.](http://images.novusbio.com/fullsize/MT-ND3-Antibody-Immunoprecipitation-NBP2-93832-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: MT-ND3 Antibody - Azide and BSA Free [MT-ND3] - Immunofluorescence analysis of HepG2 cells using MT-ND3 Rabbit pAb at dilution of 1:100 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.](http://images.novusbio.com/fullsize/nbp2-93832_rabbit-polyclonal-mt-nd3-antibody-52202516293969.jpg)
![Western Blot: ASRGL1 Antibody [NBP1-89133] - Analysis in control (vector only transfected HEK293T lysate) and ASRGL1 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Western-Blot-NBP1-89133-img0011.jpg "Western Blot: ASRGL1 Antibody [NBP1-89133] - Analysis in control (vector only transfected HEK293T lysate) and ASRGL1 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).")
![Immunocytochemistry/Immunofluorescence: ASRGL1 Antibody [NBP1-89133] - Staining of human cell line U-2 OS shows localization to nucleoplasm & microtubules. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-89133-img0004.jpg)
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Staining of human cervix, uterine, endometrium, fallopian tube and skeletal muscle using Anti-ASRGL1 antibody NBP1-89133 (A) shows similar protein distribution across tissues to independent antibody NBP2-38759 (B).](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0012.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Staining of human skeletal muscle shows no positivity in myocytes as expected.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0005.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Staining of human testis shows moderate positivity in a subset cells in seminiferous ducts.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0006.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Staining of human fallopian tube shows moderate to strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0007.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Staining of human endometrium shows moderate to strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0008.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Staining of human cervix, uterine shows moderate to strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0009.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP1-89133] - Analysis in human fallopian tube and skeletal muscle tissues. Corresponding ASRGL1 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP1-89133-img0010.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Western-Blot-NBP2-45602-img0008.jpg "Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A.")
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HepG2 cells.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0003.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Carcinoma of Human liver tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0007.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of extracts (35ug) from 9 different cell lines (HepG2: Human; HeLa: Human; HT29: Human; A549: Human; COS7: monkey; Jurkat: human; MDCK: Canine; PC12: Rat; MCF7: human)](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Western-Blot-NBP2-45602-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of COS7 cells transiently transfected by pCMV6-ENTRY CDKN2A.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HeLa cells.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0002.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Carcinoma of Human thyroid tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0004.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Adenocarcinoma of Human endometrium tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0005.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Human liver tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0006.jpg)
![Western Blot: NDUFA8 Antibody [NBP1-82661] - Analysis using Anti-NDUFA8 antibody NBP1-82661 (A) shows similar pattern to independent antibody NBP1-82662 (B).](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Western-Blot-NBP1-82661-img0007.jpg "<b>Independent Antibodies Validation. </b>Western Blot: NDUFA8 Antibody [NBP1-82661] - Analysis using Anti-NDUFA8 antibody NBP1-82661 (A) shows similar pattern to independent antibody NBP1-82662 (B).")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: NDUFA8 Antibody [NBP1-82661] - Staining of human liver.](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Immunohistochemistry-Paraffin-NBP1-82661-img0010.jpg)
![Western Blot: NDUFA8 Antibody [NBP1-82661] - Lane 1: NIH-3T3 cell lysate (Mouse embryonic fibroblast cells). Lane 2: NBT-II cell lysate (Rat Wistar bladder tumor cells).](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Western-Blot-NBP1-82661-img0005.jpg)
![Immunohistochemistry-Paraffin: NDUFA8 Antibody [NBP1-82661] - Staining of human colon shows strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Immunohistochemistry-Paraffin-NBP1-82661-img0002.jpg)
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: NDUFA8 Antibody [NBP1-82661] - Staining of human cerebral cortex, colon, kidney and liver using Anti-NDUFA8 antibody NBP1-82661 (A) shows similar protein distribution across tissues to independent antibody NBP1-82662 (B).](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Immunohistochemistry-Paraffin-NBP1-82661-img0006.jpg)
![Immunohistochemistry-Paraffin: NDUFA8 Antibody [NBP1-82661] - Staining of human kidney.](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Immunohistochemistry-Paraffin-NBP1-82661-img0008.jpg)
![Immunohistochemistry-Paraffin: NDUFA8 Antibody [NBP1-82661] - Staining of human cerebral cortex.](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Immunohistochemistry-Paraffin-NBP1-82661-img0009.jpg)
![Immunohistochemistry-Paraffin: NDUFA8 Antibody [NBP1-82661] - Staining of human colon.](http://images.novusbio.com/fullsize/NDUFA8-Antibody-Immunohistochemistry-Paraffin-NBP1-82661-img0011.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Analysis in human fallopian tube and skeletal muscle tissues. Corresponding ASRGL1 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP2-38759-img0009.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Analysis in human fallopian tube and skeletal muscle tissues. Corresponding ASRGL1 RNA-seq data are presented for the same tissues.")
![<b>Independent Antibodies Validation and Orthogonal Strategies Validation.</b>Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Staining of human cervix, uterine, endometrium, fallopian tube and skeletal muscle using Anti-ASRGL1 antibody NBP2-38759 (A) shows similar protein distribution across tissues to independent antibody NBP1-89133 (B).](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP2-38759-img0008.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: ASRGL1 Antibody [NBP2-38759] - Analysis in EFO-21 cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-ASRGL1 antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Western-Blot-NBP2-38759-img0007.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Staining of human endometrium shows moderate to strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP2-38759-img0012.jpg)
![Western Blot: ASRGL1 Antibody [NBP2-38759] - Analysis in control (vector only transfected HEK293T lysate) and ASRGL1 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Western-Blot-NBP2-38759-img0006.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Staining of human fallopian tube shows moderate to strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP2-38759-img0010.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Staining of human skeletal muscle shows no positivity in myocytes as expected.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP2-38759-img0011.jpg)
![Immunohistochemistry-Paraffin: ASRGL1 Antibody [NBP2-38759] - Staining of human cervix, uterine shows moderate to strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/ASRGL1-Antibody-Immunohistochemistry-Paraffin-NBP2-38759-img0013.jpg)
![Western Blot: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY SELENBP1.](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Western-Blot-NBP2-45979-img0008.jpg "Western Blot: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY SELENBP1.")
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Human lung tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0007.jpg)
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Adenocarcinoma of Human colon tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0001.jpg)
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Human Kidney tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0002.jpg)
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Human tonsil tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0003.jpg)
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Human lymph node tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0004.jpg)
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Carcinoma of Human kidney tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0005.jpg)
![Immunohistochemistry: SELENBP1 Antibody (3H1) [NBP2-45979] - Analysis of Human colon tissue. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min)](http://images.novusbio.com/fullsize/SELENBP1-Antibody-3H1-Immunohistochemistry-NBP2-45979-img0006.jpg)